Interview with Robert Dahan, President, AstraZeneca France
You’ve been at the head of AstraZeneca France for 7 years through during which time there has been a lot of M&A activity in the industry as well as a…
Address: 1 Place Louis Renault, Rueil-Malmaison cedex 92844,France
Tel: 33 (0)1 41 29 40 00
Web: http://www.astrazeneca.fr/accueil/
AstraZeneca provides medical professionals and patients know how and drugs already widely recognized. The French subsidiary of AstraZeneca was the first European subsidiary of the group and the third in the world after the United States and Japan.
With a turnover of 1.23 billion euros in 2008, AstraZeneca is the 6th largest pharmaceutical company in France while employing 1,900 people.
In France, AstraZeneca is involved in all stages of the life of the drug research, development, production, marketing. Besides the headquarters in Rueil-Malmaison and medical networks present throughout the territory, the company has a center of Cancer Research in Reims and two industrial sites in Dunkirk and Reims.
AstraZeneca has a broad range of effective drugs and innovative, designed to combat disease in areas where medical needs are greatest.
ANESTHESIA
HEART
GASTROINTESTINAL ENTEROLOGY
INFECTIOLOGY
ONCOLOGY
RESPIRATORY
CENTRAL NERVOUS SYSTEM
You’ve been at the head of AstraZeneca France for 7 years through during which time there has been a lot of M&A activity in the industry as well as a…
Thierry Drilhon, president of the Franco-British Chamber of Commerce, talks about Brexit, the pro-industry Macron government and his positive outlook on the future of France and Franco-British cooperation. I…
David Kimelfeld, president of Lyon Métropole, speaks out about his plans for the region in terms of industrial innovation and sustainability, describing how Lyon’s historical roots would represent and enhance…
Jean Monin, general manager of Amgen France, discusses the challenges of bringing products to market in France and what is needed to better promote biosimilars. He also talks about his…
Stewart Cole, president of Institut Pasteur, speaks out about his aspirations as the first foreign president of the institute and the main themes of the new strategic plan. Brexit…
Since 1978, Alban Muller has been a point of reference for natural ingredients in cosmetics, pharma and nutraceuticals. In this interview, Mr. Muller, founder and CEO, explains the strategic role…
Catherine Bourrienne-Bautista, Déléguée générale of the GEMME (L’association Genérique Même Medicament, France’s generics and biosimilars association), provides her take on the state of the generics and biosimilars industry in France.…
Maurice-Pierre Planel, president of the CEPS (Comité économique des produits de santé), details how the French government is unique in the way that they engage in drug pricing and comments…
Oliver Brandicourt, Sanofi’s CEO has kept his promise to steer the company back on the path to growth. This change in fortune comes after the French Pharma giant suffered losses…
As the UK prepares to leave the European Union in March 2019, stakeholders across the European life sciences industry are busy preparing for Brexit’s potential impact on their operations. In…
Thierry Philip, president of Institut Curie, talks about the organization, the effect of cancer on Social Security and the need for a cohesive European plan involving all oncology research institutions…
Ipsen global CEO David Meek provides a fascinating look into the French pharmaceutical ecosystem, Ipsen’s bold global expansion plans, its R&D transformation, and the exciting changes to come. From our…
Dr. Catherine Jessus, Director of the INSB (Institute of Biological Sciences), the largest branch of the CNRS (National Center for Scientific Research) in France, discusses the strengths and weaknesses of…
See our Cookie Privacy Policy Here
